Literature DB >> 9642624

Animal models of type I (insulin-dependent) diabetes mellitus.

D Cheţa1.   

Abstract

Much of our present knowledge concerning the etiopathogenesis, treatment and prevention of human diabetes would never have been acquired without the study of animal models of diabetes. The main models of IDDM may be divided into two groups: induced (through pancreatectomy, chemicals such as alloxan and streptozotocin, viruses and others) and spontaneous (mainly using BB rats and NOD mice). The latter, at different ages, develop a diabetic syndrome, with clinical characteristics, genetics and immunology that are very similar to the human disease. Among the more significant differences are lymphopenia (in BB rats) and the predominance of diabetes in females (in NOD mice). Studies aimed at preventing IDDM have advanced by leaps and bounds by using the two spontaneous models. These include various methods such as genomic modification, an influence over some environmental agents, immunosuppression, immunotherapy, immunomodulation and tolerance induction as well as protection of the beta-cell from autoimmune attack. The conclusions drawn from animal experiments have allowed some human trials to be carried out with encouraging results.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9642624     DOI: 10.1515/jpem.1998.11.1.11

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  16 in total

Review 1.  Alternatives to immunosuppressive drugs in human islet transplantation.

Authors:  Alison Anne Cotterell; Norma Sue Kenyon
Journal:  Curr Diab Rep       Date:  2002-08       Impact factor: 4.810

2.  Impact of experimental diabetes on the maternal uterine vascular remodeling during rat pregnancy.

Authors:  Julie K Phillips; Amanda M Vance; Renju S Raj; Maurizio Mandalà; Erika A Linder; Natalia I Gokina
Journal:  Reprod Sci       Date:  2012-03       Impact factor: 3.060

3.  Inducing immune tolerance: a focus on Type 1 diabetes mellitus.

Authors:  Dan Xu; Suchitra Prasad; Stephen D Miller
Journal:  Diabetes Manag (Lond)       Date:  2013-09-01

4.  Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity.

Authors:  T Tsutsui; B Hesabi; D S Moons; P P Pandolfi; K S Hansel; A Koff; H Kiyokawa
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

5.  Sensitization to gliadin induces moderate enteropathy and insulitis in nonobese diabetic-DQ8 mice.

Authors:  Heather J Galipeau; Nestor E Rulli; Jennifer Jury; Xianxi Huang; Romina Araya; Joseph A Murray; Chella S David; Fernando G Chirdo; Kathy D McCoy; Elena F Verdu
Journal:  J Immunol       Date:  2011-09-12       Impact factor: 5.422

Review 6.  Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models.

Authors:  M C Deeds; J M Anderson; A S Armstrong; D A Gastineau; H J Hiddinga; A Jahangir; N L Eberhardt; Y C Kudva
Journal:  Lab Anim       Date:  2011-04-08       Impact factor: 2.471

7.  Chronic diabetes alters function and expression of ryanodine receptor calcium-release channels in rat hearts.

Authors:  Keshore R Bidasee; Karuna Nallani; Bruce Henry; U Deniz Dincer; Henry R Besch
Journal:  Mol Cell Biochem       Date:  2003-07       Impact factor: 3.396

8.  Creating a long-term diabetic rabbit model.

Authors:  Jianpu Wang; Rong Wan; Yiqun Mo; Qunwei Zhang; Leslie C Sherwood; Sufan Chien
Journal:  Exp Diabetes Res       Date:  2010-12-27

9.  Promoting Effects of Streptozotocin-induced Diabetes on Induction of Hepatic Preneoplastic Lesions by Diethylnitrosamine in Rats.

Authors:  Kazuhito Ichikawa; Yoshiaki Tagawa; Masaomi Kawai; Makoto Asamoto; Tomoyuki Shirai
Journal:  J Toxicol Pathol       Date:  2010-10-05       Impact factor: 1.628

Review 10.  Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals.

Authors:  Remya Robinson; Veluchamy A Barathi; Shyam S Chaurasia; Tien Y Wong; Timothy S Kern
Journal:  Dis Model Mech       Date:  2012-07       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.